The Trump administration has announced a pilot project allowing states and non-federal government entities to import certain medicines from Canada which pays much lower prices under its single-payer system.
Eligible drugs for importation must be approved for sale in Canada and will require retesting and relabeling to ensure quality. Controlled substances, biologics, injectables and high-risk (REMS) medications are excluded.
About a dozen states have expressed a keen interest in sourcing drugs north of the border.
Another provision would allow a domestic drugmaker to import its own product from Canada.
A major hurdle is the Canadian government which has repeatedly stated that its market is too small to accomodate U.S. demand.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.